CRYOFOCUS-B (06922) announced its interim results, reporting a net loss attributable to shareholders of 15.082 million yuan, a year-on-year decrease of 36.68%.

date
18:08 28/08/2026
avatar
GMT Eight
Kangfeng Biological-B (06922) announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 40.679 million, a year-on-year decrease of 20.4%; the loss attributable to shareholders of the parent company was RMB 15.082 million, a year-on-year decrease of 36.68%; earnings per share amounted to a loss of RMB 0.06.
CRYOFOCUS-B (06922) announced its interim results for the six months ended June 30, 2026, reporting revenue of RMB 40.679 million, a decrease of 20.4% year-on-year; the loss attributable to shareholders of the parent company was RMB 15.082 million, a decrease of 36.68% year-on-year; and the loss per share was RMB 0.06. The announcement stated that the decrease in revenue was primarily due to the group proactively adjusting its sales strategy in the first half of 2026 to better align with industry development needs. As a result, the group's sales figures declined compared to the same period last year.